What is TRIO Pharmaceuticals?
TRIO Pharmaceuticals operates at the intersection of biotechnology and precision medicine, focusing on the creation of bispecific antibodies that exhibit unprecedented potency and selectivity. Unlike traditional approaches that may impact healthy tissue, TRIO's innovative drug candidates are engineered to directly inhibit tumor growth while simultaneously neutralizing immunosuppression within the tumor microenvironment. By bypassing conventional immune checkpoint pathways, the company is establishing a new paradigm in tumor immunity-enhancing therapies. The organization is led by a seasoned team of industry veterans with a proven track record of bringing first-in-class, FDA-approved oncology drugs to market, positioning the firm as a formidable player in the competitive landscape of cancer immunotherapeutics.
How much funding has TRIO Pharmaceuticals raised?
TRIO Pharmaceuticals has raised a total of $5.3M across 2 funding rounds:
Angel/Seed
$2.2M
Other Financing Round
$3.1M
Angel/Seed (2023): $2.2M with participation from Friedman Bioventures, NuFund Venture Group, and SeedFolio
Other Financing Round (2024): $3.1M led by Friedman, Life Science Angels, Multiple Myeloma Research Foundation, Myeloma Investment Fund, and NuFund Venture Group
Key Investors in TRIO Pharmaceuticals
Multiple Myeloma Research Foundation
The Multiple Myeloma Research Foundation is a global nonprofit organization dedicated to accelerating the development of next-generation therapies and personalized treatment approaches for myeloma patients.
Myeloma Investment Fund
A mission-driven venture philanthropy fund that provides strategic financial support to early-stage biotech companies developing innovative therapies for multiple myeloma.
Life Science Angels
A premier angel investment group focused on providing capital and mentorship to early-stage life science companies to foster innovation in the healthcare sector.
What's next for TRIO Pharmaceuticals?
With the successful closure of this major strategic investment, TRIO Pharmaceuticals is well-positioned to accelerate its clinical development pipeline. The company intends to leverage these resources to transition its dual-action drug candidates through critical regulatory milestones and expand its proprietary platform capabilities. As the firm moves into its next phase of growth, the focus will remain on validating the efficacy of its bispecific antibody technology in human trials. By maintaining a rigorous approach to drug discovery and leveraging the strategic guidance of its specialized investor base, TRIO is poised to address the complexities of cancer treatment, potentially offering transformative outcomes for patients suffering from high-need malignancies.
See full TRIO Pharmaceuticals company page
